In the last trading session, 4.53 million RVL Pharmaceuticals plc (NASDAQ:RVLP) shares changed hands as the company’s beta touched 1.03. With the company’s per share price at $0.12 changed hands at $0.0 or 2.17% during last session, the market valuation stood at $13.35M. RVLP’s last price was a discount, traded about -2350.0% off its 52-week high of $2.94. The share price had its 52-week low at $0.09, which suggests the last value was 25.0% up since then. When we look at RVL Pharmaceuticals plc’s average trading volume, we note the 10-day average is 7.7 million shares, with the 3-month average coming to 2.00 million.
Analysts gave the RVL Pharmaceuticals plc (RVLP) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 0 recommended RVLP as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. RVL Pharmaceuticals plc’s EPS for the current quarter is expected to be -$0.09.
RVL Pharmaceuticals plc (NASDAQ:RVLP) trade information
Instantly RVLP was in green as seen at the end of in last trading. With action 13.95%, the performance over the past five days has been green. The jump to weekly highs of 0.1350 on Friday, 09/15/23 added 2.17% to the stock’s daily price. The company’s shares are showing year-to-date downside of -89.06%, with the 5-day performance at 13.95% in the green. However, in the 30-day time frame, RVL Pharmaceuticals plc (NASDAQ:RVLP) is -40.82% down. Looking at the short shares, we see there were 1.36 million shares sold at short interest cover period of 0.66 days.
The consensus price target for the stock as assigned by Wall Street analysts is $3.15, meaning bulls need an upside of 96.19% from its current market value. According to analyst projections, RVLP’s forecast low is $1.60 with $6.00 as the target high. To hit the forecast high, the stock’s price needs a -4900.0% plunge from its current level, while the stock would need to soar -1233.33% for it to hit the projected low.
RVL Pharmaceuticals plc (RVLP) estimates and forecasts
Data shows that the RVL Pharmaceuticals plc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -90.20% over the past 6 months, a 1.72% in annual growth rate that is considerably lower than the industry average of 9.70%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for RVL Pharmaceuticals plc will rise 43.80%, while the growth in revenue is estimated to hit 50.00% for the next quarter. Year-over-year growth is forecast to reach -29.20% down from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of $6.6 million. 2 analysts are of the opinion that RVL Pharmaceuticals plc’s revenue for the quarter ending Dec 2023 will be $9.59 million. The company’s revenue for the corresponding quarters a year ago was $10.02 million and $9.81 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -34.10%. The estimates for the next quarter sales put growth at -2.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 9.70%. The 2023 estimates are for RVL Pharmaceuticals plc earnings to increase by 53.20%.
RVL Pharmaceuticals plc is expected to release its next quarterly earnings report between November 08 and November 13.
RVL Pharmaceuticals plc (NASDAQ:RVLP)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 27.01% of RVL Pharmaceuticals plc shares while 49.10% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 67.27%. There are 49.10% institutions holding the RVL Pharmaceuticals plc stock share, with Athyrium Capital Management, LP the top institutional holder. As of Jun 29, 2023, the company held 13.11% of the shares, roughly 14.6 million RVLP shares worth $8.18 million.
Rovida Advisors Inc. holds the second largest percentage of outstanding shares, with 2.69% or 3.0 million shares worth $1.68 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Meridian Contrarian Fund and Vanguard Extended Market Index Fund. With 1.51 million shares estimated at $0.84 million under it, the former controlled 1.35% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.20% of the shares, roughly 0.22 million shares worth around $0.13 million.